Specifications Manual for Joint Commission National Quality Measures (v2020B1)
Posted: 3/30/2020
Home » Nimodipine Administration

Release Notes:
Data Element
Version 2020B1

Name:Nimodipine Administration
Collected For: CSTK-06
Definition:Documentation that nimodipine was administered at this hospital. Nimodipine is a cerebroselective calcium channel blocker that inhibits calcium transport into vascular smooth muscle cells, thereby suppressing contractions. Nimodipine is used in the treatment of subarachnoid hemorrhage patients to prevent or limit the severity of cerebral vasospasm.
Question:Is there documentation that nimodipine was administered at this hospital?
Format:
Length:1
Type:Alphanumeric
Occurs:1
Allowable Values:

Y (Yes) Nimodipine was administered at this hospital.

N (No) Nimodipine was not administered at this hospital,OR unable to determine from medical record documentation.
Notes for Abstraction:
  • Nimodipine treatment must be administered at this hospital within the first 24 hours of arrival to select “'YES'. It is not necessary to review documentation outside of this timeframe.
  • If nimodipine was administered at another hospital and the patient was subsequently transferred to this hospital and nimodipine treatment continued on admission to this hospital, select “'YES'”.
  • If nimodipine was administered at this hospital later than the first 24 hours after arrival, select 'NO'.
  • If nimodipine was administered at another hospital and the patient was subsequently transferred to this hospital and nimodipine treatment was not resumed or discontinued, select “'NO'.
  • A physician order for nimodipine that is not executed, select “'NO'”.
Suggested Data Sources:
  • Emergency department record
  • Nursing flow sheet
  • Progress notes
  • Medication administration record (MAR)
  • Medical transport records
  • Medication reconciliation form
Additional Notes:
Guidelines for Abstraction:
Inclusion Exclusion
  • Nimodipine
  • Nimotop
  • Nymalize

All other calcium channel blocker medications other than those listed as inclusions.

Nimodipine Administration
CPT® only copyright 2019 American Medical Association. All rights reserved.
Specifications Manual for Joint Commission National Quality Measures (v2020B1)
Discharges 07-01-20 (3Q20) through 12-31-20 (4Q20)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

CPT® only copyright 2019 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.

^